SVRA Stock Summary and Trading Ideas (Savara | NASDAQ:SVRA)

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara trades on the NASDAQ stock market under the symbol SVRA.

As of March 20, 2026, SVRA stock price declined to $4.96 with 6,547,082 million shares trading.

SVRA has a beta of 1.06, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.08 to the broad based SPY ETF.

SVRA has a market cap of $1.02 billion. This is considered a Small Cap stock.

In the last 3 years, SVRA traded as high as $7.01 and as low as $1.63.

The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, VXF, XBI, IWO.

SVRA has outperformed the market in the last year with a return of +73.4%, while the SPY ETF gained +16.6%. However, in the most recent history, SVRA shares have underperformed the stock market with its stock returning -18.0% in the last 3 month period and -5.9% for the last 2 week period, while SPY has returned -4.4% and -3.3%, respectively.

SVRA support price is $4.97 and resistance is $5.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA shares will trade within this expected range on the day.